XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2022     7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 $ 66,578 $ 8 $ 574,548 $ (29) $ (507,241) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (6,187) (6,187)       (6,187)    
Share-based compensation (in shares)     132,000          
Share-based compensation 589 589   589        
Unrealized loss on marketable securities (11) (11)     (11)      
Foreign currency translation adjustment (12) (12)     (12)      
Common stock, ending balance (in shares) at Mar. 31, 2023     7,999,000          
Ending balance at Mar. 31, 2023 $ 60,703 60,957 $ 8 575,137 (52) (513,428) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2023 8,149,897   8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 48,148 $ 8 576,971 (42) (528,081) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,401) (5,401)       (5,401)    
Share-based compensation (in shares)     157,000          
Share-based compensation 312 312   312        
Unrealized loss on marketable securities (13) (13)     (13)      
Foreign currency translation adjustment $ (49) (49)     (49)      
Common stock, ending balance (in shares) at Mar. 31, 2024 8,307,433   8,308,000          
Ending balance at Mar. 31, 2024 $ 42,743 $ 42,997 $ 8 $ 577,283 $ (104) $ (533,482) $ (708) $ (254)